Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UN Head Says 17 Drug Makers Promise More AIDS Research For Poor

This article was originally published in PharmAsia News

Executive Summary

The head of the United Nations says major drug and diagnostics makers have promised to increase their research into AIDS drugs and diagnostics that are more affordable in poorer nations. Secretary-General Ban Ki-Moon said the companies also have agreed to invest more in developing vaccines, prophylactic treatments and prevention programs. Ban said he negotiated the agreement with 17 companies, including the major multinational firms. He said current efforts are not keeping up with an epidemic that continues to grow faster than it can be treated. (Click here for more

You may also be interested in...

Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance

Swiss biotech Molecular Partners will receive upfront payment of CHF 60m, including equity.

Experts Call For Unifying Measures For EU Political And Regulatory Oversight

Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU, not least through increasing costs and impacting device availability.

IVDR Implementation Not Yet On Track: What The Diagnostics Sector Needs To Do

It’s time to focus on how the diagnostics sector will comply with the EU’s IVD Regulation. TÜV SÜD expert, Andreas Stange, explains why the IVD industry could be in trouble and what must be done now.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts